InspireMD announces publication of CREST-2 data in NEJM

InspireMD (NSPR) announced the recent presentation and publication of CREST-2 data which demonstrated positive clinical outcomes for carotid artery stenting for patients with asymptomatic carotid stenosis. CREST-2 data was shown at The Society of Vascular and Interventional Neurology Annual Meeting and the Vascular and Endovascular Issues Techniques and Horizons Symposium on November 21, 2025. In conjunction, the CREST-2 study was published in the New England Journal of Medicine. CREST-2 showed that, among patients with high-grade carotid stenosis without recent neurological symptoms, the addition of stenting led to significantly better outcomes than intensive medical management alone, as measured by a decreased risk of the composite of perioperative stroke or death or ipsilateral stroke within 4 years. In a separate arm of the same trial, carotid endarterectomy did not achieve a significant benefit for these patients as compared to intensive medical management alone. “The publication of CREST-2 data is an important moment for the treatment of carotid disease,” said Peter Soukas, M.D., Chief Medical Advisor. “These data meaningfully clarify the role of carotid stenting as a front-line treatment for patients with asymptomatic carotid stenosis, confirming the results that many of us in the field have achieved for a long time. Physicians and patients now have definitive, high-quality evidence that CAS is an effective treatment option for these patients.”